anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Tumour dormancy, a resistance mechanism employed by cancer cells, is a significant challenge in cancer treatment, contributing to minimal residual disease (MRD) and potential relapse. Despite its clinical importance, the mechanisms underlying tumour dormancy and MRD remain unclear. In this study, we employed two syngeneic murine models of myeloid leukemia and melanoma to investigate the genetic, epigenetic, transcriptomic and protein signatures associated with tumour dormancy. We used a multiomics approach to elucidate the molecular mechanisms driving MRD and identify potential therapeutic targets.
RESULTS: We conducted an in-depth omics analysis encompassing whole-exome sequencing (WES), copy number variation (CNV) analysis, chromatin immunoprecipitation followed by sequencing (ChIP-seq), transcriptome and proteome investigations. WES analysis revealed a modest overlap of gene mutations between melanoma and leukemia dormancy models, with a significant number of mutated genes found exclusively in dormant cells. These exclusive genetic signatures suggest selective pressure during MRD, potentially conferring resistance to the microenvironment or therapies. CNV, histone marks and transcriptomic gene expression signatures combined with Gene Ontology (GO) enrichment analysis highlighted the potential functional roles of the mutated genes, providing insights into the pathways associated with MRD. In addition, we compared "murine MRD genes" profiles to the corresponding human disease through public datasets and highlighted common features according to disease progression. Proteomic analysis combined with multi-omics genetic investigations, revealed a dysregulated proteins signature in dormant cells with minimal genetic mechanism involvement. Pathway enrichment analysis revealed the metabolic, differentiation and cytoskeletal remodeling processes involved in MRD. Finally, we identified 11 common proteins differentially expressed in dormant cells from both pathologies.
CONCLUSIONS: Our study underscores the complexity of tumour dormancy, implicating both genetic and nongenetic factors. By comparing genomic, transcriptomic, proteomic, and epigenomic datasets, our study provides a comprehensive understanding of the molecular landscape of minimal residual disease. These results provide a robust foundation for forthcoming investigations and offer potential avenues for the advancement of targeted MRD therapies in leukemia and melanoma patients, emphasizing the importance of considering both genetic and nongenetic factors in treatment strategies.
OBJECTIVE: The feature of Parkinson's disease (PD) is the heavy dopaminergic neuron loss of substantia nigra pars compacta (SNpc), while glutaredoxin (GLRX) has been discovered to modulate the death of dopaminergic neurons. In this context, this study was implemented to uncover the impact of GRX1 on motor dysfunction and dopamine neuron degeneration in PD mice and its potential mechanism.
METHODS: A PD mouse model was established via injection with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into mice. After gain- and loss-of-function assays in mice, motor coordination was assessed using rotarod, pole, and open-field tests, and neurodegeneration in mouse SNpc tissues was determined using immunohistochemistry of tyrosine hydroxylase and Nissl staining. NRF1, methyltransferase-like 3 (METTL3), and GLRX expression in SNpc tissues were evaluated using qRT-PCR, Western blot, and immunohistochemistry. The N6-methyladenosine (m6 A) levels of GLRX mRNA were examined using MeRIP. The relationship among NRF1, METTL3, and GLRX was determined by RIP, ChIP, and dual luciferase assays.
RESULTS: Low GLRX, METTL3, and NRF1 expression were observed in MPTP-induced mice, accompanied by decreased m6 A modification level of GLRX mRNA. GLRX overexpression alleviated motor dysfunction and dopamine neuron degeneration in MPTP-induced mice. METTL3 promoted m6 A modification and IGF2BP2-dependent stability of GLRX mRNA, and NRF1 increased METTL3 expression by binding to METTL3 promoter. NRF1 overexpression increased m6 A modification of GLRX mRNA and repressed motor dysfunction and dopamine neuron degeneration in MPTP-induced mice, which was counteracted by METTL3 knockdown.
CONCLUSION: Conclusively, NRF1 constrained motor dysfunction and dopamine neuron degeneration in MPTP-induced PD mice by activating the METTL3/GLRX axis.
A humic acid sticky rice compound and its process, includes a sticky rice peptide original potions is use sticky rice to obtain peptide solution through enzymatic hydrolysis. A raw material of humic acid is use powder shape fulvic acid. The raw material of humic acid is mixed with the sticky rice peptide original potions. The raw material of humic acid is dissolved in the sticky rice peptide original potions, and made into a compound of humic acid sticky rice peptide. The mixing weight ratio of humic acid sticky rice peptide compound is 80~93% sticky rice peptide original potions mixed with 7~20% raw material of humic acid. Provide a humic acid sticky rice compound and its process, refers to a humic acid sticky rice peptide compound. Has the complementary effect of humic acid and sticky rice peptide. The function of improving the absorption rate of sticky rice peptide.
BACKGROUND: Emerging evidence suggests a central role for inflammation in cardiac conduction disorder (CCD). It is unknown whether habitual physical activity could modulate the inflammation-associated risks of incident CCD in the general population.
METHODS AND RESULTS: This population-based cohort was derived from the China Kailuan study, including a total of 97 192 participants without prior CCD. The end points included incident CCD and its subcategories (atrioventricular block and bundle-branch block). Systemic inflammation was indicated by the monocyte-to-lymphocyte ratio (MLR). Over a median 10.91-year follow-up, 3747 cases of CCD occurred, with 1062 cases of atrioventricular block and 2697 cases of bundle-branch block. An overall linear dose-dependent relationship was observed between MLR and each study end point (all P-nonlinearity≥0.05). Both higher MLR and physical inactivity were significantly associated with higher risks of conduction block. The MLR-associated risks of developing study end points were higher in the physically inactive individuals than in those being physically active, with significant interactions between MLR levels and physical activity for developing CCD (P-interaction=0.07) and bundle-branch block (P-interaction<0.05) found. Compared with those in MLR quartile 2 and being physically active, those in the highest MLR quartile and being physically inactive had significantly higher risks for all study end points (1.42 [95% CI, 1.24-1.63], 1.62 [95% CI, 1.25-2.10], and 1.33 [95% CI, 1.13-1.56], respectively, for incident CCD, atrioventricular block, and bundle-branch block).
CONCLUSIONS: MLR should be a biomarker for the risk assessment of incident CCD. Adherence to habitual physical activity is favorable for reducing the MLR-associated risks of CCD.
PURPOSE:To provide the subject chelating agent consisting of a polyalkylenepolyamine polyacetic acid derivative, having excellent contrast- enhancing capability, stability and durability in blood, free from high osmotic pressure and useful as an agent for diagnostic imaging and diagnostic for arteriosclerosis, etc. CONSTITUTION:The objective chelating agent consisting of a compound expressed by formula IV (R3 to R<6> are OH or group of formula V) (e.g. diethylenetriamine pentaacetic acid diamide) can be produced by dehydrating a polyalkylenepolyamine polyacetic acid compound of formula I [R1 and R2 are H or lower alkyl; (m) is integer of 1-3] (e.g. diethylenetriamine pentaacetic acid) to form an acid dianhydride derivative of formula II (e.g. diethylenetriamine pentaacetic acid dianhydride) and reacting the anhydride with a compound of formula III (A is H, lower alkyl, lower alkoxy, halogen or trifluoromethyl; B is alkyl or alkenyl; Y is alkylene; X1 is NH2 or OH; (n) is 0 or 1) (e.g. 4-octylaniline).
Tissue nanotransfection (TNT) topically delivers Etv2, Foxc2, and Fli1 (EFF) plasmids increasing vasculogenic fibroblasts (VF) and promoting vascularization in ischemic murine skin. Human dermal fibroblasts respond to EFF nanoelectroporation with elevated expression of endothelial genes in vitro, which is linked to increased ten-eleven translocase 1/2/3 (TET) expression. Single cell RNA sequencing dependent validation of VF induction reveals a TET-dependent transcript signature. TNTEFF also induces TET expression in vivo, and fibroblast-specific EFF overexpression leads to VF-transition, with TET-activation correlating with higher 5-hydroxymethylcytosine (5-hmC) levels in VF. VF emergence requires TET-dependent demethylation of endothelial genes in vivo, enhancing VF abundance and restoring perfusion in diabetic ischemic limbs. TNTEFF improves perfusion and wound closure in diabetic mice, while increasing VF in cultured human skin explants. Suppressed in diabetes, TET1/2/3 play a critical role in TNT-mediated VF formation which supports de novo blood vessel development to rescue diabetic ischemic tissue.
Patients receive SGT-53 IV over 90-120 minutes on days 1, 8, and 15, pembrolizumab IV over 30 minutes on day 3, and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
A-medical device withan emotion measuring finger sheathing means incorporating with a long- distance control includes a finger sheathing means (1), which has a temperature sensing assembly (11) capable of sensing the finger temperature, a processing unit (12) and a wireless transmitting transceiver unit (13) inside, and is provided with a finger sheathing means (14) capable of sheathing on the finger outside. The position of the temperature sensing assembly (11) just corresponds to the skin surface of the finger. The processing unit (12) is electrically connected to the temperature sensing assembly (11) and can perform an operation to the signal measured by the temperature sensing assembly (11). The transceiver unit (13) is electrically connected to the processing unit (12). The acquired finger temperature data is transmitted wirelessly to the long- distance medical device through the transceiver unit (13) by the processing unit (12) by wireless. The long distance control medical device (2) is provided with a transceiver module (21) connected to the transceiverunit (13) inside, and a control unit (22) electrically connected to the transceiver module (21). The control unit (22) is also electrically connected to the input and output unit (23), so that the operation of transmittingthe desired delivering command set by the controlunit (22) to the finger sheathing means (1) to perform measurement is provided.
Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
Methods and systems for promoting mobile awareness are described. In an embodiment, a location associated with a member of a drug benefit plan is accessed. A drug benefit plan action is determined based on the location associated with the member. The drug benefit plan action is an action at least partially at the direction of a pharmacy benefit manager that administers the drug benefit plan. A drug benefit notification is generated based on the drug benefit plan action. The pharmacy notification benefit is associated with the drug benefit plan. Additional methods and systems are disclosed.
Subjects meeting the eligibility criteria, including parental informed consent to collect clinical-epidemiological information, will have a deep respiratory aspirate specimen to determine the etiology of the lower respiratory tract infection. Clinicians may obtain other diagnostic specimens, such as pleural fluid, lung tap, cerebrospinal fluid, nasopharyngeal culture, or serum for serological assays, as indicated clinically. The chest radiograph will be taken and read locally according to predetermined criteria and by staff radiologists trained in radiographic criteria for pneumonia. Bacterial isolates other than Streptococcus pneumoniae will be identified according to standardized procedures. S. pneumoniae isolates will be transported to central laboratories for confirmation of identity, serotyping and antibiotic resistance testing, using standard techniques. Serotype will be determined using type-specific sera (Quellung reaction). Antibiotic susceptibility to penicillin, cefuroxime, ceftriaxone, erythromycin, Amoxycillin, Ofloxacin, Vancomycin, and imipenem be conducted using E-test according to standardized procedures at the central facilities.
BACKGROUND AND OBJECTIVE: This study aims to define specific measurements on cranial high-resolution computed tomography (HRCT) images prior to surgery to prove the feasibility of the navigated transmastoid infralabyrinthine approach (TI-A) without rerouting of the facial nerve (FN) and decompression of the jugular bulb (JB) in accessing the extradural-intrapetrous part of petrous bone lesions located at the petrous apex and petroclival junction.
MATERIALS AND METHODS: Vertical and horizontal distances of the infralabyrinthine space were measured on cranial HRCT images prior to dissection. Subsequently, the area of access was measured on dissected human cadaveric specimens. Infralabyrinthine access to the extradural part of the petrous apex and petroclival junction was evaluated on dissected specimens by two independent raters. Finally, the vertical and horizontal distances were correlated with the area of access.
RESULTS: Fourteen human cadaveric specimens were dissected bilaterally. In 54% of cases, the two independent raters determined appropriate access to the petrous apex and petroclival junction. A highly significant positive correlation (r = 0.99) was observed between the areas of access and the vertical distances. Vertical distances above 5.2 mm were considered to permit suitable infralabyrinthine access to the extradural area of the petrous apex and petroclival junction.
CONCLUSIONS: Prior to surgery, vertical infralabyrinthine distances on HRCT images above 5.2 mm provide suitable infralabyrinthine access to lesions located extradurally at the petrous apex and petroclival junction via the TI-A without rerouting of the FN and without decompression of the JB.
This is Phase III study to evaluate the anti-infective efficacy and safety of D-PLEX, a new formulation of extended release of Doxycycline, over a period of 3 months post operation by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. Study will be conducted in about 45 sites in US (about 15 sites), Europe and Israel, recruitment period will last about 18 months. D-PLEX will be administered as a single application. For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment. For subjects randomized to the control arm, the surgical treatment will be as per the SOC. Pre- and post-operative care for both arms will be performed per site SOC. Patients will followed-up during 6 months after surgery.
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Composition includes a combination of sterile, purified from toxins filtrate phagolysates bacteria with lytic activity of not less than 10PFU/ml by agar-layer technique in relation to most frequently extracted from surface of cooled fish strains of bacteria. Composition contains: phage lysate filtrate Aeromonas veronii, obtained using a strain of bacteriophage Aeromonas phage Ave1, deposited in the All-Russian State Collection of Pathogenic and Vaccines Strains of Microorganisms-Agents of Infectious Animal Diseases of K. I. Scriabin and Ya. R. Kovalenko All-Russian Research Institute of Experimental Veterinary Medicine of the Russian Academy of Science under number BF-1359; a phagolysate filtrate Brothothrix thermosilica obtained using a strain of the bacteriophage Brochothrix phage Brother1 deposited in the All-Russian State Collection of Pathogenic and Vaccines Strains of Microorganisms-Agents of Infectious Animal Diseases of K. I. Scriabin and Ya. R. Kovalenko All-Russian Research Institute of Experimental Veterinary Medicine of the Russian Academy of Science under number BF-1360; phagolysate filtrate Buttiauxella gaviniae obtained using bacteriophage strain Buttiauxella phage Buga1, deposited in the All-Russian State Collection of Pathogenic and Vaccines Strains of Microorganisms-Agents of Infectious Animal Diseases of K. I. Scriabin and Ya. R. Kovalenko All-Russian Research Institute of Experimental Veterinary Medicine of the Russian Academy of Science under number BF-1361; phlegolysate filtrate Pseudomonas fluorescens obtained using a strain of bacteriophage Pseudomonas fluorescens Pf 1, deposited in the State Collection of Pathogenic Microorganisms and Cell Cultures of the State Scientific Center of Applied Microbiology and Biotechnology under number Ph-132; phagolysate filtrate Aeromonas hydrophila, obtained using a bacteriophage strain of Aeromonas hydrophila Ah 1, deposited in the State Collection of Pathogenic Microorganisms and Cell Cultures of the State Scientific Center of Applied Microbiology and Biotechnology under number Ph-129; phagolysate filtrate Raoultella ornithinolytica, obtained using Raoultella ornithinolytica R.o. 1 bacteriophage strain, deposited in State Collection of Pathogenic Microorganisms and Cell Cultures of State Research Center of Applied Microbiology and Biotechnology under number Ph-128; phagolysate filtrate Listeria monocytogenes obtained using a strain of bacteriophage Listeria monocytogenes Lm 1, deposited in the State Collection of Pathogenic Microorganisms and Cell Cultures of State Research Center of Applied Microbiology and Biotechnology under number Ph-133. Disclosed are also corresponding strains of bacteriophages and nucleic acid molecules corresponding to the genome of said bacteriophages.EFFECT: presented is a phage-mediated bioprocessing method for prolonging shelf life of cooled fish and reducing the risk of infections and an antibacterial composition for implementing the method.9 cl, 15 tbl, 10 ex
Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
Certain embodiments of the present invention provide systems and methods for interruption workflow management in a clinical enterprise. Certain embodiments provide an interruption workflow management system for a clinical enterprise. The system includes a worklist including a plurality of patient indicators representing patients for which tasks are to be performed by a user. The system also includes a patient panel displaying patient information associated with a patient indicator selected from the worklist. The system further includes a patient indicator shelf holding one or more patient indicators from at least one of the worklist and the patient panel for later retrieval in response to user input. The patient indicator shelf facilitates restoration of a patient indicator from the patient indicator shelf to display in the patient panel in response to user input.
A method and system for biometric and psychometric based content display. The method includes storing a psychometric assessment instrument as a data structure on a mobile device. The psychometric assessment instrument includes user data for ascertaining a user’s psychometric identity. A server collects and tags content by attribute for each specific classification of the plurality of psychometric classifications. The content is further organized across three state classes and cross-referenced with a plurality of interests. A pulse rate is measured using a camera on the mobile device. The pulse rate is measured using temporal color contrast between two frames. The pulse rate is converted to a heart rate variability (HRV) measure, which is used to designate a current state class using an artificial intelligence (AI) model. The state class is used to automatically retrieve appropriate coaching media content for consumption on the mobile device.
Low back pain (LBP) is one of the primary causes of disability worldwide. Most people-between 50% and 80%-experience LBP at some point in their life. It limits the ability to perform daily activities, such as walking, standing, or lifting objects. It can also lead to decreased mobility, reduced work productivity, and increased healthcare costs. Radiating pain is commonly caused by lumbar intervertebral disk abnormalities, which are linked with nerve root irritation and affect 3% to 10% of people with generalized low back pain. Sciatica, another name for lumbar radiculopathy, is a disorder marked by pain, weakness, numbness, or tingling sensations that radiate down the lower back along a nerve root, frequently into the buttock, thigh, and lower leg. One or more lumbar nerve roots are usually compressed, irritated, or inflamed as a reason.
Caregivers will be invited to complete a self-administered questionnaire online via a personalized electronic message. Caregivers will be free to participate. Signed consent will not be requested, but the return of the questionnaire will be considered consent. The questionnaire will be administered using Google form® software. Caregivers will have 2 weeks to respond. A reminder will be made at 7 days. The questionnaire will be anonymized upon receipt by the investigator.
This study is a randomized, prospective, active-controlled, single-center, open label, dose-ranging clinical trial of TIV (Fluzone®) administered to healthy 18-to-49 year old adults who did not receive 2003-2004, 2004-2005 and 2005-2006 influenza vaccine. Subjects will be randomized to one of 7 groups (4 intramuscular and 3 intradermal) to compare the immunogenicity and safety of different concentrations of the standard Fluzone® administered intradermally using the Mantoux technique to that of standard Fluzone® administered intramuscularly. The primary objective of the study is to compare the immunogenicity of injected Fluzone® across different dose levels and different routes of administration. The secondary objectives are to describe the number and proportions of subjects in each group experiencing any injection site or systemic symptoms and the proportion of subjects who experience moderate-to-severe symptoms post vaccination. Approximately 31 subjects per group (217 in total) will be enrolled with each group determined by dose and route of administration of vaccines. Subjects will be observed in the clinic for at least 30 minutes after immunization and will maintain a memory aid to record daily oral temperature and any systemic and local reactions for 7 days after the day of immunization. Subjects will be contacted by phone between 8 to 12 days after immunization to review their 7-day memory aid, including the assessment of their recorded daily oral temperature, any local or systemic reactions, and the occurrence of any other AEs and SAEs. Subjects will return at 28 (+/- 3) days after immunization to assess the occurrence of unsolicited AEs and SAEs and complete an acceptability and functional skill questionnaire. Serum for immunogenicity evaluations will be obtained prior to the first vaccination and approximately 28 (+/- 3) days post vaccination. The 2005-2006 formulation will be used for all seven groups.